Modulation of carnitine palmitoyltransferase-1 for the treatment of obesity.
The rising incidence of obesity, as a disorder of energy metabolism, has provoked a search for pharmacological agents that either increase energy expenditure or reduce food intake. The fatty acid oxidation pathway, and its rate-limiting enzyme carnitine palmitoyltransferase (CPT)-1 are potential targets for the treatment of obesity. The modulation of CPT-1 may simultaneously affect energy metabolism and food intake to aid in the management of obesity. Both the inhibition and enhancement of CPT-1 activity are currently under investigation as strategies for the treatment of obesity. In this review, key data on both sides of the 'CPT-1 activity balance' as they relate to obesity therapy are discussed.
Kuhajda
Francis P
FP
The Johns Hopkins University School of Medicine, Department of Pathology, UMB BioPark, Building 1, 800 West Baltimore Street, Suite 150, Baltimore, MD 21201, USA. fkuhajda@jhmi.edu
Ronnett
Gabriele V
GV
D000818:Animals; D002334:Carnitine O-Palmitoyltransferase / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D004789:Enzyme Activation / Q000187:drug effects; D005227:Fatty Acids / Q000378:metabolism; D006801:Humans; D007783:Lactones / Q000494:pharmacology / Q000627:therapeutic use; D008954:Models, Biological; D015394:Molecular Structure; D009765:Obesity / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology
D005227:Fatty Acids; D007783:Lactones; D002334:Carnitine O-Palmitoyltransferase